|Bid||64.70 x 300|
|Ask||64.71 x 700|
|Day's Range||64.31 - 64.75|
|52 Week Range||63.88 - 88.85|
|PE Ratio (TTM)||6.82|
|Dividend & Yield||2.08 (3.22%)|
|1y Target Est||N/A|
Gilead Sciences (GILD), however, has not only not participated, its shares have continued to drop in 2017. Gilead Sciences has continued to suffer from declining sales of its hepatitis-C drugs, and concerns about competition in HIV, as well. At the same time, the market is still waiting for Gilead to buy a company to help knock it out of the doldrums.
Gilead Sciences Inc said on Tuesday a combination of its experimental HIV drug with existing therapies met the main goal in four late-stage studies. Gilead, which already has approved treatments for HIV, is pinning its hope on the combination to better compete with Britain's GlaxoSmithKline Plc, which is working on two-drug treatment regimen for controlling the virus behind AIDS. The U.S. drugmaker evaluated the addition of its experimental drug, bictegravir, to emtricitabine/tenofovir alafenamide (FTC/TAF), which are already in use to treat HIV.
Gilead Sciences Inc. said pre-market Tuesday that an HIV drug combination met primary endpoints in four late-stage clinical trials. The company said it plans to file for approval in the U.S. and Europe ...